#1 Clinical Trials Search in Europe

Azd5004

AZD5004 is a novel drug currently undergoing clinical trials for the treatment of obesity and type 2 diabetes. This article explores the ongoing research into AZD5004’s safety, efficacy, and potential benefits for patients struggling with weight management and blood sugar control. We’ll examine the various phases of clinical trials and what they aim to discover about this promising new medication.

Table of Contents

What is AZD5004?

AZD5004, also known as ECC5004, is a new drug currently being developed and tested for the treatment of type 2 diabetes and obesity[1]. It is an oral medication that is taken once daily in the form of a film-coated tablet[2]. This drug is still in the experimental stage and is not yet approved for general use. Researchers are conducting various clinical trials to determine its effectiveness and safety.

What Conditions Does AZD5004 Treat?

Based on the ongoing clinical trials, AZD5004 is being studied for its potential to treat:

  • Type 2 Diabetes Mellitus: This is a chronic condition that affects how your body processes glucose (sugar). AZD5004 is being tested to see if it can help control blood sugar levels in people with type 2 diabetes[2].
  • Obesity: The drug is also being studied for its potential to help with weight loss in people who are living with obesity (BMI ≥ 30 kg/m2) or who are overweight (BMI ≥ 27 kg/m2) with at least one weight-related health condition[4].

How Does AZD5004 Work?

While the exact mechanism of action is not fully described in the provided information, we can infer some details based on the study outcomes being measured:

  • Blood Sugar Control: AZD5004 appears to help control blood sugar levels. Researchers are measuring changes in HbA1c (a long-term measure of blood sugar control) and fasting glucose levels[2].
  • Weight Loss: The drug seems to have an effect on body weight. Studies are looking at percent change in body weight and the proportion of participants achieving significant weight loss[4].
  • Insulin Sensitivity: There are indications that AZD5004 might improve insulin sensitivity, as researchers are measuring changes in HOMA-IR (a measure of insulin resistance)[3].

Current Clinical Trials

Several clinical trials are currently underway to test AZD5004:

  • Phase I Trials: These are early studies in healthy volunteers and people with type 2 diabetes to test the safety, tolerability, and how the drug is processed in the body (pharmacokinetics)[1][3].
  • Phase IIb Trials: These more advanced studies are testing different doses of AZD5004 in people with type 2 diabetes and obesity to determine its effectiveness and further assess its safety[2][4].

How is AZD5004 Administered?

AZD5004 is taken orally as a film-coated tablet once daily[2]. The exact dosage is still being determined through the clinical trials, with different studies testing various dose levels to find the most effective and safe dose.

Safety and Potential Side Effects

As AZD5004 is still in the testing phase, its full safety profile is not yet known. The clinical trials are closely monitoring for any adverse events (side effects). Some key points about safety:

  • Researchers are tracking the number of participants who experience adverse events and serious adverse events[3].
  • The studies are also monitoring vital signs, laboratory tests, and physical examinations to ensure participant safety.
  • Specific side effects are not mentioned in the provided information, as this data is still being collected.

Future Prospects for AZD5004

The development of AZD5004 represents a potential new treatment option for people with type 2 diabetes and obesity. If the clinical trials show positive results, this drug could offer several benefits:

  • A new option for blood sugar control in type 2 diabetes
  • Potential for significant weight loss in people with obesity
  • Convenience of once-daily oral dosing

However, it’s important to note that AZD5004 is still in the experimental stage. More research is needed to fully understand its effectiveness and safety before it can be considered for approval and general use. Patients interested in new treatments for diabetes or obesity should discuss current options with their healthcare provider.

Aspect Details
Drug Name AZD5004 (also known as ECC5004)
Administration Oral tablet, typically once daily
Target Conditions Obesity, Overweight with comorbidities, Type 2 Diabetes Mellitus
Clinical Trial Phases Phase I, Phase IIb
Primary Outcomes Weight loss, Glycemic control (HbA1c reduction)
Secondary Outcomes Changes in body weight, BMI, waist circumference, fasting glucose, insulin sensitivity
Safety Assessments Adverse events, vital signs, ECG, laboratory tests
Special Populations Studied Patients with hepatic impairment, renal impairment, Japanese participants
Duration of Treatment Varies by study, ranging from single dose to 36 weeks
Comparators Placebo, Semaglutide (in some trials)

FAQ

  • What is AZD5004? AZD5004 is an experimental drug being studied for its potential to treat obesity and type 2 diabetes. It is currently in clinical trials to evaluate its safety, effectiveness, and how it works in the body.
  • What conditions is AZD5004 being tested for? AZD5004 is primarily being tested for obesity, overweight with weight-related health issues, and type 2 diabetes. Clinical trials are examining its effects on weight loss and blood sugar control.
  • How is AZD5004 administered? In the clinical trials, AZD5004 is being administered as an oral tablet, typically taken once daily. The exact dosage may vary depending on the specific trial and phase of research.
  • What are the main goals of the AZD5004 clinical trials? The main goals are to assess the safety and tolerability of AZD5004, determine its effectiveness for weight loss and blood sugar control, understand how the body processes the drug (pharmacokinetics), and evaluate its effects on the body (pharmacodynamics).
  • Are there any known side effects of AZD5004? As AZD5004 is still in clinical trials, the full range of potential side effects is not yet known. The trials are designed to monitor and record any adverse events to establish the safety profile of the drug.

Ongoing Clinical Trials on Azd5004

  • Study on the Effects of AZD5004 and Semaglutide for Adults with Type 2 Diabetes

    Not recruiting

    1 1
    Investigated drugs:
    Germany Hungary Poland Slovakia Spain

  • Study on the Effects of AZD5004 for Adults with Obesity or Overweight and a Related Medical Condition

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Body Mass Index (BMI): A measure used to assess body fat based on height and weight. It's often used to categorize individuals as underweight, normal weight, overweight, or obese.
  • Type 2 Diabetes Mellitus (T2DM): A chronic condition that affects the way your body processes blood sugar (glucose), characterized by high blood sugar levels due to insulin resistance or insufficient insulin production.
  • HbA1c: A blood test that measures your average blood sugar levels over the past 2-3 months, used to diagnose and monitor diabetes.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare against the effects of the drug being tested.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
  • Hepatic Impairment: A condition where the liver is not functioning properly, which can affect how drugs are processed in the body.
  • Renal Impairment: A condition where the kidneys are not functioning properly, which can affect how drugs are eliminated from the body.

References

  1. https://clinicaltrials.gov/study/NCT06555822
  2. https://clinicaltrials.gov/study/NCT06579105
  3. https://clinicaltrials.gov/study/NCT06703658
  4. https://clinicaltrials.gov/study/NCT06579092